News

by: Debbie de la Riva The collective pursuit to control the spread of coronavirus has resulted in an enormous challenge for the…

NHF’s Bleeding Disorders Conference was fully virtual this year and included more than 50 sessions. Those sessions are all available on-demand until…

Last month, BioMarin learned that approval for their investigational hemophilia A gene therapy was not forthcoming but would in fact be delayed…

On September 1, 2020, NHF and HFA learned that  Mylan N.V. is conducting a voluntary nationwide recall of  four lots of Tranexamic Acid Injection,…

The National Hemophilia Foundation (NHF) has received a five-year cooperative agreement from the Centers from Disease Control and Prevention (CDC). The collaboration,…

BioMarin is committed to updating the community regarding our ongoing gene therapy clinical trial program in hemophilia A. BioMarin’s investigational gene therapy…

Biomarin announced that they received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on August 18th for their…

Novo Nordisk has announced that clinical trials for their investigational subcutaneous therapy concizumab will resume after an approximate five month pause, initiated…

August 13, 2020 CSL Behring and Ferring Pharmaceuticals have announced additional information about a recent recall of lots of Stimate® that was…

Hemophilia is an inherited bleeding disorder in which the blood does not clot properly due to a lack or decrease in a…

Individuals with inherited and acquired bleeding disorders, including hemophilia have substantial deficits in coagulation, for which they receive a variety of protein…

In 2019, the National Hemophilia Foundation conducted a series of listening sessions and guided conversations with Black and African American members of…

Ferring Pharmaceuticals issued a voluntary recall of Stimate (desmopressin) nasal spray due to “superpotency” – in other words, amounts of desmopressin being higher than…

On July 21, CSL Behring and Ferring Pharmaceuticals announced a recall of multiple lots of Stimate (desmopressin) in the United States and in other countries…

The National Hemophilia Foundation (NHF) and Takeda have teamed up to launch a series of PSAs and resources that hope to increase…

At the National Hemophilia Foundation’s (NHF) Bleeding Disorders Conference, held virtually this year, NHF president and CEO Leonard Valentino, MD, asked each…

A paper published in the journal Haemophilia, suggests that clinical expectations for people with hemophilia have remained relatively static for years, falling…

It is well established that the clinical management of pregnant women with congenital bleeding disorders (CBDs) is challenging, as healthcare providers, including…

Immediately following the issuance of medical advisories to the community regarding the recall of Stimate® (desmopressin nasal spray ) a product used to control…

Ferring Pharmaceuticals Inc. is initiating a precautionary voluntary recall of all batches of Stimate® Nasal Spray (desmopressin acetate) 1.5 mg/mL. During testing…

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the second interim analysis of the…

The Partners in Bleeding Disorders Education Program has announced the launch of a new online learning module, “Accounting for Home Care: The Role…

CSL Behring recently announced that it has agreed to acquire exclusive global license rights from uniQure, to commercialize etranacogene dezaparvovec (AMT-061), an…

Sanofi and Sobi, along with the World Federation of Hemophilia (WFH) and WFH USA recently announced as extension of the two companies’…